2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 619

Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 628

Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 616

Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 770

Integrating Analysis of Skin RNA in Situ Hybridization Using Rnascope and Whole Skin Gene Expression in Systemic Sclerosis Skin to Localize Key Pathogenic Drivers of Skin Fibrosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 351

Integration of Electronically Captured Patient-Reported Outcomes in a Pediatric Rheumatology Clinic Visit

Patient Outcomes, Preferences, and Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 166

Integrative Systems Biology Approach Identifies Key Transcription Factors and Novel Rheumatoid Arthritis (RA) and Individualized Therapeutic Targets

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 203

Intensive Care Unit Admissions Among Patients with Rheumatic Diseases at a Tertiary Care Center

Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 754

Interferon Siganture in Systemic Sclerosis Lung Microvascular Endothelial Cells

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 367

Interleukin-1 Receptor Antagonist Is a Potential Treatment for Undifferentiated Autoinflammatory Syndromes

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Autoinflammatory Disorders and Miscellaneous

9:00AM-11:00AM: Abstract Number: 634

International League of Associations for Rheumatology. Systematic Review of the Literature to Inform Treatment Recommendations for Psoriatic Arthritis in Resource-Poor Countries

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 599

Intravenous Golimumab in Adult Patients with Active Psoriatic Arthritis: Efficacy and Safety through Week 24

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 177

Intronic Variants of the B-Cell Proliferator RASGRP3 Affect Its Expression, and Might Contribute to Lupus Risk

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 652

Investigating the Role of Mechanical Stress in Spondyloarthritis Pathogenesis

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 51

Irisin Ameliorates Infrapatellar Adiposity in Knee Osteoarthritis Pathogenesis By Orchestrating Adipokine Signaling

Biology and Pathology of Bone and Joint Poster I

9:00AM-11:00AM: Abstract Number: 629

Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].